MedTrace Logo

Genetics of Hypertension Associated Treatments (GenHAT)

NCT00006294 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37939

Last updated 2024-04-26

No results posted yet for this study

Summary

To examine whether the association between selected hypertensive genes and combined fatal coronary heart disease and nonfatal myocardial infarction in high-risk hypertensives is modified by the type of antihypertensive treatment, leading to differential risks of coronary heart disease.

Conditions

Interventions

DRUG

Chlorthalidone

participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study

DRUG

Lisinopril

participant's drug dose will be titrated from 10mg to 40mg over the course of the study

DRUG

Amlodipine

participant's drug dose will be titrated from 10mg to 40mg over the course of the study

DRUG

Doxazosin

participant's drug dose will be titrated from 2mg to 8mg over the course of the study

Sponsors & Collaborators

  • University of Minnesota

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Donna Arnett, 257-5678

    lead OTHER

Principal Investigators

  • Donna Arnett · University of Kentucky

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2005-08-31
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006294 on ClinicalTrials.gov